IRB approval expired

To evaluate cardiac MRI and/or serum biomarkers for detecting cardiac cardiac toxicity in children who received anthracycline based chemotherapy (ABC).

Cardiac toxicity is a significant potential complication for patients receiving anthracycline chemotherapy. Cells in the cardiovascular system have limited regenerative capability, making them susceptible to long term adverse effects from these chemotherapeutic agents. The ability to detect subclinical changes in cardiac function will allow clinicians to use proven treatments to prevent further progression in this vulnerable population. The current standard testing uses echocardiography, which is not as sensitive as cardiac MRI or serum biomarkers.

Inclusion Criteria:

• Subjects that have received anthracycline based chemotherapy
• Age: 8 years old - 25 years old
• Subjects that do not require sedation for cardiac MRI.
• Subjects must have completed treatment in the last 10 years

Exclusion Criteria:

• Patients with significant congenital heart defects
• Patients with renal injury or renal failure, defined as an estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2 body surface area), as previously calculated)
• Patients that require sedation for a cardiac MRI
• Subjects that are pregnant or lactating
• Patients with contraindications to a cardiac MRI:
• Cardiac pacemaker or implantable defibrillator
• Cerebral aneurysm clip
• Neural stimulator
• Metallic ocular foreign body
• Any implanted device (i.e. insulin pump, drug infusion device)
• Claustrophobia
• Metal shrapnel or bullet
• Investigator assessment of inability to comply with protocol
• Unable/unwilling to lie still throughout the research procedure
• Persons with cognitive impairment

Patients with previous exposure to anthracyclines between the ages of 8-25 years of age.